Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (81.3%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (18.7%; Sandoz).
Net sales break down geographically as follows: Switzerland (1.7%), Germany (9.4%), France (4.9%), Europe (23.1%), the United States (32.6%), the Americas (7%), China (5.9%), Japan (5.2%) and Asia-Africa-Australasia (10.2%).
Number of employees : 104 323 people.
2020 2021 Delta Innovative Medicines 36 618.10 80.2% 38 394.60 81.3% +4.85% Sandoz 9 053.87 19.8% 8 805.30 18.7% -2.75%
CHF in Million
2020 2021 Delta United States 15 472.10 33.9% 15 376.10 32.6% -0.62% Europe 10 282.50 22.5% 10 909.00 23.1% +6.09% Asia/Africa/Australasia 4 544.77 10% 4 782.53 10.1% +5.23% Germany 4 240.66 9.3% 4 452.48 9.4% +4.99% Canada and Latin America 3 042.05 6.7% 3 332.50 7.1% +9.55% China 2 415.05 5.3% 2 790.34 5.9% +15.54% Japan 2 631.87 5.8% 2 452.98 5.2% -6.8% France 2 292.10 5% 2 305.78 4.9% +0.6% Switzerland 750.89 1.6% 798.16 1.7% +6.29%
CHF in Million
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
2,403,721,252
2,092,926,588
87.1% 252,740,811
10.5% 87.1%
Shareholders Novartis AG (CH0012005267) Novartis AG (US) Novartis AG (CH0038459415) Novartis AG (ARDEUT112521) Novartis AG (BRN1VSBDR006)
Name Equities % Novartis AG 282,034,061
11.7% Sandoz Family Foundation 89,135,960
3.71% The Vanguard Group, Inc. 59,871,605
2.49% UBS Asset Management Switzerland AG 55,730,682
2.32% Norges Bank Investment Management 50,631,295
2.11% Credit Suisse Asset Management (Schweiz) AG 50,012,984
2.08% Wellington Management Co. LLP 48,697,381
2.03% Novartis Foundation For Employee Participation 47,834,052
1.99% Dodge & Cox 20,024,470
0.83% Artisan Partners LP 18,087,944
0.75%
Name Equities % Dodge & Cox 21,048,657
0.88% PRIMECAP Management Co. 17,453,150
0.73% Loomis, Sayles & Co. LP 14,929,752
0.62% Franklin Mutual Advisers LLC 7,110,172
0.30% Dimensional Fund Advisors LP 6,503,191
0.27% Managed Account Advisors LLC 5,534,681
0.23% Wellington Management Co. LLP 5,087,602
0.21% Charles Schwab Investment Management, Inc. 4,527,461
0.19% Charles Schwab Investment Advisory, Inc. 4,398,928
0.18% ThomasPartners, Inc. 3,842,741
0.16%
Name Equities % Voya Investment Management Co. LLC 27,606
- LUKB Expert Fondsleitung AG 56,194
- Sabadell Asset Management SA SGIIC SU 525
-
Name Equities % Dimensional Fund Advisors Ltd. 8,636
0.0001% Gemmer Asset Management LLC 140
0.0000%
Name Equities % Caixa DTVM SA 372,894
0.0016%
Name Equities % Valuation
NOVARTIS AG (NOVN) 282,034,061
11.7%
25,481,221,804 USD
NOVARTIS INDIA LIMITED (500672) 17,450,680
70.7%
142,381,320 USD
ERASCA, INC. (ERAS) 12,307,692
8.94%
53,046,153 USD
PLIANT THERAPEUTICS, INC. (PLRX) 2,153,526
4.42%
41,627,658 USD
POSEIDA THERAPEUTICS, INC. (PSTX) 5,908,089
6.87%
31,312,872 USD
SOMALOGIC, INC. (SLGC) 10,422,469
5.56%
26,160,397 USD
MOLECULAR PARTNERS AG (MOLN) 1,739,130
4.82%
11,579,162 USD
GAMIDA CELL LTD. (GMDA) 4,336,759
5.83%
5,594,419 USD
TSCAN THERAPEUTICS, INC. (TCRX) 916,101
4.84%
1,419,957 USD
AYALA PHARMACEUTICALS INC
698,777
4.71%
279,511 USD
- Primary listing
- SMI / FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
- Reuters Code :
NOVN.S
- Datastream Code :
Company contact information
Novartis AG
Lichtstrasse 35
CH-4056 Basel, Basel-Stadt
Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site :
http://www.novartis.com
Novartis earnings slip 4% on strong dollar, Gilenya competition
NOVARTIS AG
Sector Other Pharmaceuticals
Connections : Novartis AG
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
